Opportunity
Federal Register #B-118-2026
Proposed Production Activity for Active Pharmaceutical Ingredients at Olon USA LLC (FTZ 40)
Buyer
Department of Commerce, Foreign-Trade Zones Board
Posted
September 24, 2026
Identifier
B-118-2026
NAICS
325412
This opportunity involves a proposed production activity at Olon USA LLC in Concord, Ohio, within Foreign-Trade Zone 40, overseen by the Department of Commerce's Foreign-Trade Zones Board. - Government Buyer: - Department of Commerce, Foreign-Trade Zones Board - FTZ 40 (Cleveland-Cuyahoga County Port Authority) - OEM Highlight: - Olon USA LLC (manufacturer of active pharmaceutical ingredients) - Products/Services Requested: - Manufacturing of active pharmaceutical ingredients (APIs): - API D Cancer Treatment Drug Product - API R1 Breast Cancer Treatment Product - API I Kidney Disorder Treatment Product - API R2 Chronic Urticaria Treatment Product - API A Ph+CML Cancer Treatment Product - Use of foreign-status materials/components: - Kinase Inhibitor - Enzyme B-Raf Inhibitor - Oral Complement Inhibitor - Oral Bruton's Tyrosine Kinase Inhibitor - Protein Kinase Inhibitor - Succinic Acid - Methanesulfonic Acid - Plastic Bags - Foil Bags - Notable Requirements: - Duty rates for finished APIs range from 3.7% to 6.5%; materials/components range from 3% to 6.5% - Some materials are subject to special duties under section 232 or section 301, depending on country of origin, and must be admitted to FTZs in privileged foreign status - No specific purchase quantities or part numbers provided - Public comment is invited on the proposed activity
Description
The Department of Commerce, through the Foreign-Trade Zones Board, has announced a proposed production activity at Olon USA LLC, located in Concord, Ohio, within Foreign-Trade Zone 40. This activity involves the manufacturing of active pharmaceutical ingredients including various cancer and treatment products. The notification specifies the use of certain foreign-status materials and components subject to duties under trade laws. Public comments are invited until November 3, 2026, and further information can be obtained from the Board's Executive Secretary.